NDA.FI

15.87

+0.13%↑

BKT

13.902

-2.06%↓

FCFS

221.87

+1.13%↑

RAND

25.365

+0.54%↑

NDA.FI

15.87

+0.13%↑

BKT

13.902

-2.06%↓

FCFS

221.87

+1.13%↑

RAND

25.365

+0.54%↑

NDA.FI

15.87

+0.13%↑

BKT

13.902

-2.06%↓

FCFS

221.87

+1.13%↑

RAND

25.365

+0.54%↑

NDA.FI

15.87

+0.13%↑

BKT

13.902

-2.06%↓

FCFS

221.87

+1.13%↑

RAND

25.365

+0.54%↑

NDA.FI

15.87

+0.13%↑

BKT

13.902

-2.06%↓

FCFS

221.87

+1.13%↑

RAND

25.365

+0.54%↑

Home・Akcijų sąrašas・Sartorius Stedim Biotech.

Search

Sartorius Stedim Biotech.

Atidarymo kaina

SektoriusFinansų sektorius

154.75 -0.99

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

154.8

Max

157.7

Pagrindiniai rodikliai
By Trading Economics
Pajamos	41M 88M
Pardavimai	-11M 762M
P/E Sektoriaus vid.	58.498 37.736
Pelnas, tenkantis vienai akcijai	1.17
Pelno marža	11.569
Darbuotojai	10,456
EBITDA	26M 225M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+48.69% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-07-23

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-2.6B 16B
Ankstesnė atidarymo kaina	155.74
Ankstesnė uždarymo kaina	154.75

Naujienos nuotaikos

By Acuity

13%

87%

17 / 439 reitingas Finance

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

202.7 / 211.7 Palaikymas ir pasipriešinimas

Sartorius Stedim Biotech. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-04 22:17; UTC

Uždarbis

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

2026-05-04 23:47; UTC

Uždarbis

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

2026-05-04 23:45; UTC

Uždarbis

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

2026-05-04 23:45; UTC

Uždarbis

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

2026-05-04 23:40; UTC

Rinkos pokalbiai

Gold Steady Amid Likely Technical Recovery -- Market Talk

2026-05-04 22:44; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Jim Beyer To Be Chief Executive of Combined Company

2026-05-04 22:43; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

2026-05-04 22:42; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

2026-05-04 22:42; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

2026-05-04 22:41; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

2026-05-04 22:41; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Pro Forma Market Capitalization About A$10.7 Billion

2026-05-04 22:40; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Shareholders to Own About 51% of Combined Company

2026-05-04 22:40; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Board Unanimously Endorsed, Supported Deal

2026-05-04 22:40; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Deal Unanimously Recommended by Vault Board

2026-05-04 22:39; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

2026-05-04 22:38; UTC

Įsigijimai, susijungimai, perėmimai

Regis Resources to Acquire All Ordinary Shares in Vault

2026-05-04 22:38; UTC

Įsigijimai, susijungimai, perėmimai

Regis Resources, Vault Minerals Agree to Merger of Equals

2026-05-04 22:37; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

2026-05-04 22:26; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

2026-05-04 22:02; UTC

Uždarbis

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

2026-05-04 22:00; UTC

Rinkos pokalbiai

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

2026-05-04 21:52; UTC

Uždarbis

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

2026-05-04 21:50; UTC

Uždarbis

Westpac: Some Sectors More Affected Than Others>WBC.AU

2026-05-04 21:50; UTC

Uždarbis

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

2026-05-04 21:49; UTC

Uždarbis

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

2026-05-04 21:44; UTC

Uždarbis

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

2026-05-04 21:44; UTC

Uždarbis

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

2026-05-04 21:43; UTC

Uždarbis

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

2026-05-04 21:41; UTC

Uždarbis

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

2026-05-04 21:40; UTC

Uždarbis

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Akcijų palyginimas

Kainos pokytis

Sartorius Stedim Biotech. Prognozė

Kainos tikslas

By TipRanks

48.69% į viršų

12 mėnesių prognozė

Vidutinis 233 EUR 48.69%

Aukščiausias 262 EUR

Žemiausias 210 EUR

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sartorius Stedim Biotech. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

7

Pirkti

1

Laikyti

0

Parduoti

Remiantis 8 analitikų, pateikusių Sartorius Stedim Biotech. akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

202.7 / 211.7Palaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Rinkos nuotaikos

By Acuity

17 / 439 reitingas Finansų sektorius

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.

Kitos sektoriaus akcijos

NDA.FI

Nordea Bank Abp

15.87

BKT

Bankinter SA

13.902

FCFS

FirstCash Inc

221.87

RAND

Randstad Holding NV

25.365

Live chat